Boston Scientific Wins Major Stent Contract: CNBC's Huckman

Boston Scientific has landed an exclusive contract to provide drug-coated stents to the Cleveland Clinic, one of the nation's most prominent cardiology centers, CNBC pharmaceuticals reporter Mike Huckman has learned.

Cleveland Clinic has signed a two-year contract to buy only Boston Scientific stents in a deal valued at about $18 million a year, a source told Huckman.

A spokesperson for the clinic said Boston Scientific has "preferred vendor status." But Huckman said two sources, including one who was very close to the contract negotiations, said it's an "exclusive" deal.

Although the contract isn't huge in the multi-billion dollar stent business, the prominence of the Cleveland Clinic is a big boost for Boston Scientific and a potential blow to rival Johnson &Johnson, which has been selling stents to the clinic.

Because stents--and drug coated ones in particular--have such high profit margins, every little shift in market share can have an impact on the bottom line.

This is a major turnaround by the Cleveland Clinic, which only two years ago stopped using Boston Scientific's stent following a recall over an implantation device problem.

"This was not a decision based on science," a source told Huckman. "It was financially driven."
The labs where stents are implanted are profit centers for most hospitals.

Stents are the tiny wire mesh tubes that prop open clogged arteries. Drug-coated stents have come under increased scrutiny recently because of the possibility they could cause blood clots. Huckman said this deal was struck before the blood clot issue came became widely known.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More*

Don't Miss

U.S. Video

  • CNBC's Tyler Mathisen looks back at the week's top business and financial stories. The markets were closed for Thanksgiving, but did manage to hit new highs. Low oil prices gave consumers more money to spend for Black Friday.

  • Cyber Monday deals on Walmart's website on Dec. 2, 2013.

    CNBC's Tyler Mathisen looks ahead to what are likely to be next week's top stories. The jobs report comes out this week, as do auto sales. And the Rockefeller Center Christmas tree is lit.

  • Following last week's wild energy ride, analysts expect oil prices to continue to drop during the holiday season. CNBC's Patti Domm reports.